Home / Stocks / Biofil Chem & Pharma Ltd
BIOFILCHEM

Biofil Chem & Pharma Ltd Share Price

Live price, chart and which mutual funds hold this stock

…

as of —

₹—

Change

—

Day Open

₹—

Day High

₹—

Day Low

₹—

NSE Close — 25 Sep 2026

₹32.44

Change

+0.11 (0.34%)

Open

₹32.11

Prev. Close

₹32.33

Day High

₹32.98

Day Low

₹32.11

Volume Analysis

Traded

5,741

Delivered

3,961

Delivery %

68.99%

End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.

Pivot Levels

Type R3 R2 R1 Pivot S1 S2 S3
Classic ₹33.78 ₹33.38 ₹32.91 ₹32.51 ₹32.04 ₹31.64 ₹31.17
Fibonacci ₹33.38 ₹33.05 ₹32.84 ₹32.51 ₹32.18 ₹31.97 ₹31.64
Camarilla ₹32.68 ₹32.6 ₹32.52 ₹32.51 ₹32.36 ₹32.28 ₹32.2

Support/resistance levels for today, calculated from the previous trading day's high/low/close.

Absolute Returns

YTD

-1.64%

1 Week

-0.52%

1 Month

-1.49%

3 Months

-7.16%

6 Months

+17.75%

1 Year

-21.87%

2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.

Company Overview

Sector

Healthcare

Source: Screener.in (Consolidated figures) — data as of 23 Sep 2026. Not investment advice.

TopFund Analysis

Biofil Chem & Pharma Ltd lands in the middle of the pack on TopFund's composite fundamentals check within the Healthcare sector, at 54/100. The strongest factor is Corporate Governance (85/100), while Institutional Ownership (30/100) is the weakest area to weigh before deciding.

TopFund Score — Fundamentals Quality

54/100 — Average

Data confidence: 60/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.

As of 27 Sep 2026 · How we calculate this →

Corporate Governance

85

Institutional Ownership

30

Risk & Volatility

49

Liquidity

49

Not investment advice — an automated read of public fundamentals data, for research context only.

Corporate Actions

Pursuant to Regulation 30, 44 and 47 of SEBI(LODR) Regulations, 2015 and in compliance with Section 108 of the Companies Act, 2013 read with rule …

41st AGM on 23 September 2026; annual report and notice shared with shareholders lacking registered emails.

Company issued 2025-26 annual report; 41st AGM on 23 Sept 2026, including ₹20 crore related-party approval.

Source: BSE regulatory filings, via Screener.in.

Shareholding Pattern

Quarter-by-quarter — Promoters, FII, DII & public holding trend

Promoter holding: 46.82% → 46.79%
  Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026
Public 53.1% 53.11% 53.08% 53.11% 53.1% 53.11% 53.11% 53.1% 53.12% 53.13% 53.12% 53.13%
Promoters 46.82% 46.82% 46.82% 46.82% 46.82% 46.82% 46.82% 46.82% 46.79% 46.79% 46.79% 46.79%
FII 0.0% 0.0% 0.03% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
DII 0.08% 0.08% 0.08% 0.08% 0.08% 0.08% 0.08% 0.08% 0.08% 0.08% 0.08% 0.08%

Source: Screener.in — quarterly shareholding disclosures.

Peers Comparison

Healthcare — ranked by market cap

Company Market Cap (Cr) P/E P/B ROE
Biofil Chem & Pharma Ltd (this stock) — — — —
Sun Pharmaceutical Ind L 444,405 35.2 5.32 16.0%
Divi S Laboratories Ltd 255,487 85.8 15.25 16.5%
Torrent Pharmaceuticals L 189,746 85.0 20.11 27.4%
Apollo Hospitals Enter. L 128,055 60.9 13.51 21.2%
Zydus Lifesciences Ltd 115,890 23.8 4.32 21.2%
Cipla Ltd 111,060 31.0 3.23 11.6%

Which Mutual Funds Hold Biofil Chem & Pharma Ltd?

Frequently Asked Questions about Biofil Chem & Pharma Ltd

Community Sentiment

What are other investors saying about Biofil Chem & Pharma Ltd?

No votes yet — be the first to share your view.

Sign in to vote

Discussion

User-generated content — not investment advice, and not verified or endorsed by TopFund.

Sign in to join the discussion

No comments yet — start the discussion.